Current Report Filing (8-k)
April 23 2018 - 05:03AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 12,
2018
Creative Medical Technology Holdings,
Inc.
(Exact name of registrant as specified in
its charter)
Nevada
|
|
000-53500
|
|
87-0622284
|
(State or other jurisdiction of
incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification No.)
|
2017 W Peoria Avenue, Phoenix, AZ 85029
|
(Address of principal executive offices)
|
Registrant’s telephone number, including
area code:
(602) 680-7439
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
x
Emerging growth company If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
¨
|
Item 3.02
|
Unregistered Sales of Equity Securities.
|
From April 12, 2018 through April 19, 2018,
we issued an aggregate of 114,017,952 shares upon the conversions of outstanding notes and 15,009,325 shares upon the cashless
exercise of outstanding warrants. These conversions were made pursuant to the exemption provided by Section 3(a)(9) of the Securities
Act of 1933. As a result of these issuances, we have outstanding 609,062,989 shares of common stock as of April 19, 2018.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Creative Medical Technology Holdings, Inc.
|
|
|
Date: April 20, 2018
|
By:
|
/s/ Donald Dickerson
|
|
|
Donald Dickerson, CFO
|